Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Van, Joanna
QWINT-5, NCT05463744: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy	Completed	3	692	Europe, Japan, US, RoW	Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec	Eli Lilly and Company	Type 1 Diabetes, Diabetes	05/24	05/24
SURMOUNT-5, NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities	Completed	3	751	US	Tirzepatide, LY3298176, Semaglutide	Eli Lilly and Company	Obesity, Overweight	11/24	11/24
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes	Active, not recruiting	3	1500	Europe, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Type 2 Diabetes	08/25	08/25
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities	Active, not recruiting	3	3000	Europe, Japan, US, RoW	Orforglipron, LY3502970, Placebo	Eli Lilly and Company	Obesity, Overweight, Overweight or Obesity	07/25	07/27
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec	Recruiting	2	230	US	HDV-Lispro, HDV-L, Lispro, LIS	Diasome Pharmaceuticlas, Inc.	Diabetes Mellitus, Type 1	06/25	12/25